SBIR/STTR Research Award

Raising the Therapeutic Index of Photodynamic Therapy with Targeted Nanosyringes

Award identifier 867bc9a14e0ab44a2857d43f0c521d62482474081b51025b6066224214c2ba98Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$299,945

Program and phase

STTR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NANOHYBRIDS INC
Proposal award date
2017-09-05
Contract end date
2019-09-04
UEI
D7SFBJJHZ9Y5
Solicitation number
PA16-303
Topic code
102

Research abstract

ABSTRACT Current clinical photodynamic therapy PDT is an effective cancer treatment that is non invasive and low cost but it has yet to become a mainstream frontline treatment The clinical efficacy of PDT in solid tumors depends on significant accumulation of the photosensitizer PS at the tumor site availability of oxygen near the photosensitizer and effective dosing of the drug light combination Our new platform for delivery and imaging of photosensitizers entitled nano enabled PDT nePDT will enhance all three of these areas raising PDT s therapeutic index and enabling PDT to reach its full clinical potential nePDT comprises a core of oxygen rich liquid perfluorocarbon PFC containing indocyanine green ICG dye stabilized by a lipid shell which houses the photosensitizer PS and also provides binding sites for cancer cell targeting antibodies The ICG dye is used to trigger a liquid to gas phase change of the PFC which serves two purposes it delivers PS and additional O to the cell cytosol acting as a nanosyringe and the vaporization event creates a giant acoustic transient which can be detected using combined photoacoustic and ultrasound PAUS imaging and used to visualize the distribution of drug delivery at the tumor site From the rich D spatial information received by PAUS imaging of the drug distribution light intensity and duration dosimetry for effective PDT can be calculated This personalized dosimetry will ensure patients receive the correct therapy dose customized for their tumor The promise of PDT to provide localized therapy with minimal residual damage or side effects to healthy tissues is remarkable We are excited to introduce this new nePDT platform that will enhance specific delivery of PS to the tumor increase efficacy of therapy through O delivery especially to hypoxic tumors and ultimately create a personalized patient specific dose enabled by PAUS imaging While PDT has the potential to treat a variety of diseases we chose head and neck cancer generally and specifically oral cancer for an initial target application due to the unmet clinical need for minimal intervention minimal scarring to reduce cosmetic and functional defects and the superficial location of these tumors which provides light accessibility nePDT is a revolutionary new nanoplatform capable of removing the roadblocks to widespread therapeutic efficacy and clinical success for PDT NARRATIVE Current clinical photodynamic therapy PDT is an effective cancer treatment that is non invasive and low cost but it has yet to become a mainstream frontline cancer therapy The clinical efficacy of PDT in solid tumors depends on significant accumulation of the photosensitizer PS at the tumor site availability of oxygen near the photosensitizer and effective dosing of the drug light combination Our new platform for delivery and imaging of photosensitizers entitled nano enabled PDT nePDT will significantly enhance all three of these areas enabling PDT to reach its full clinical potential

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

7 SBIR/STTR records share this UEI (2012–2018). Reported award amounts total $1,621,952. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.